Of these AQPs, reduced expressions of AQP6 or AQP7 were associated with responders to aromatase inhibitors for Luminal A subtype breast cancer, whereas reduced AQP8 expression was associated with responders to anthracycline treatment for Luminal A subtype breast cancer (Figures 4A–C). This evidence concerns the gene CYP19A1 and breast carcinoma.